Stockscreener 앱 받기
1.54
4.05%
0.06
시간 외 거래:
1.56
0.02
+1.30%
전일 마감가:
$1.48
열려 있는:
$1.51
하루 거래량:
467.05K
Relative Volume:
0.52
시가총액:
$35.39M
수익:
-
순이익/손실:
$-8.09M
주가수익비율:
-3.537
EPS:
-0.4354
순현금흐름:
$-7.37M
1주 성능:
-12.00%
1개월 성능:
+14.93%
6개월 성능:
+42.59%
1년 성능:
-8.33%
1일 변동 폭
$1.51
$1.65
1주일 범위
$1.47
$1.79
52주 변동 폭
$0.85
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
명칭
NanoViricides Inc
전화
203-937-6137
주소
1 Controls Drive, Shelton, CT
Compare NNVC vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.54 | 34.01M | 0 | -8.09M | -7.37M | -0.4354 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-16 | 개시 | Alliance Global Partners | Buy |
| 2015-02-11 | 개시 | Midtown Partners | Strong Buy |
NanoViricides Inc 주식(NNVC)의 최신 뉴스
NanoViricides Inc (NNVC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
EDGAR Filing Documents for 0001104659-26-086797 - SEC.gov
Form 424B5 NanoViricides Inc For: 27 July By Investing.com - Investing.com Canada
Form 424B5 NANOVIRICIDES, INC. - StreetInsider
NNVC Stock Up 17% Today: What’s Driving The Rally? - Stocktwits
As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola - ACCESS Newswire
NanoViricides, Inc. Revenue Breakdown – AMEX:NNVC - TradingView
NanoViricides, Inc. (NNVC) Stock Price, News, Quote & History - Yahoo! Finance Canada
NanoViricides Inc (NNVC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NanoViricides Inc (NNVC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NanoViricides Raises $3.8 Million in Registered Direct Offering to Fund Antiviral Drug Development - citybuzz -
NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering - Lelezard
NanoViricides prices offering with 2,516,339 warrants at US$ 1.75 exercise price - Bitget
NanoViricides Seeks Approval for Phase II Ebola Trial in DRC Amid Ongoing Outbreak - citybuzz -
NanoViricides (NYSE:NNVC) Draws Attention After Clinical Update - Kalkine Media
DRC Ebola outbreak tops 930 deaths; NanoViricides seeks trial approval - Stock Titan
Nanoviricides Company Profile & Introduction - Moomoo
Form 424B5 NanoViricides Inc For: 17 July By Investing.com - Investing.com South Africa
Form 424B5 NanoViricides Inc For: 17 July - Investing.com UK
NanoViricides Establishes ATM Equity Sales Agreement - TipRanks
NanoViricides Inc. (NNVC) Q2 2026 Earnings: Narrowed Loss Beats Expectations; Stock RisesROE Trend Analysis - dars.gov.et
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of EbolaNanoViricides Proposal is Approved by the Pillar Committee in DR Congo - ACCESS Newswire
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - Treasure Coast News
Noble Financial Maintains Nanoviricides(NNVC.US) With Buy Rating, Maintains Target Price $6 - Moomoo
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - Treasure Coast News
NanoViricides Secures Ethics Approval for Phase II Ebola Trial in DRC - citybuzz -
As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo - ACCESS Newswire
Oral Ebola drug gummies clear key ethics hurdle as Congo outbreak widens - Stock Titan
NNVC Stock In The Limelight After This Analyst Sees A 350% Upside Potential – Everything To Know About Its Experimental Drug For Ebola - Stocktwits
NanoViricides Receives Outperform Rating and $6 Price Target from Noble Capital Markets - citybuzz -
NanoViricides Inc. (NNVC) Q2 2026 Earnings: EPS Beat but No Revenue; Stock Declines 1.01%Earnings Revision Upgrade - dars.gov.et
Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily - ACCESS Newswire
symbol__ Stock Quote Price and Forecast - CNN
NanoViricides Price Target Announced at $6.00/Share by Noble Capital Markets - Moomoo
Noble Capital initiates NanoViricides stock with Outperform rating By Investing.com - Investing.com South Africa
Noble Financial Initiates Nanoviricides(NNVC.US) With Buy Rating, Announces Target Price $6 - Moomoo
NanoViricides Advances NV-387 Oral Gummies Toward Phase II Trial for Bundibugyo Ebola in DRC - citybuzz -
Noble Capital initiates NanoViricides stock with Outperform rating - Investing.com
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo - ACCESS Newswire
NanoViricides moves NV-387 oral gummies toward DRC Ebola trial - Stock Titan
Enterprise value to revenue forward of NanoViricides, Inc. – AMEX:NNVC - TradingView
NNVCNanoViricides Inc Website Traffic and Mobile Apps Usage - Finviz
Price to book forward of NanoViricides, Inc. – AMEX:NNVC - TradingView
Enterprise value to revenue forward of NanoViricides, Inc. – SWB:NV3P - TradingView
Enterprise value to EBITDA forward of NanoViricides, Inc. – AMEX:NNVC - TradingView
NNVC Q2 2026 Earnings: Narrower-than-Expected Loss as R&D Pipeline AdvancesOne-Time Gain Impact - DonanımHaber
Price to earnings forward of NanoViricides, Inc. – AMEX:NNVC - TradingView
Ebola Global Health Emergency Needs a Broad-Spectrum DrugNV-387 is a Strong Potential Candidate, Says NanoViricides - ACCESS Newswire
NNVC Q2 2026 Earnings: Narrower-than-Expected Loss Provides a Positive SurpriseEarnings Weakness Phase - dars.gov.et
NNVC Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Stock MovementOperating Income Trends - dars.gov.et
NanoViricides Inc (NNVC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):